Zymeworks (NYSE: ZYME) reported Q1 EPS of $. Revenue for the quarter came in at $200 thousand, versus $0 reported last year.

As of March 31, 2017, Zymeworks had $26.8 million in cash and cash equivalents and short-term investments, as well as $1.9 million in SR&ED and IRAP receivables. On May 3, 2017, subsequent to the first quarter, Zymeworks completed its initial public offering for a total of $58.5 million in aggregate gross proceeds.

For earnings history and earnings-related data on Zymeworks (ZYME) click here.